Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Suzuken Co's Debt-to-Equity or its related term are showing as below:
TSE:9987's Debt-to-Equity is not ranked *
in the Medical Distribution industry.
Industry Median: 0.475 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Suzuken Co Debt-to-Equity Related Terms
Suzuken Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Suzuken Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:9987 vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Suzuken Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzuken Co Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Suzuken Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Suzuken Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzuken Co (TSE:9987) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Suzuken Co and its competitors. According to the industry distribution chart, Suzuken Co ranks #999999 out of 100 companies in the Medical Distribution industry.
Is Suzuken Co's Debt-to-Equity too high?
Suzuken Co's current Debt-to-Equity is 0.00. Based on the distribution chart, Suzuken Co ranks #999999 out of 100 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Suzuken Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzuken Co's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Suzuken Co ranks #999999 out of 100 companies for Debt-to-Equity. This places Suzuken Co in the lower half of its industry. The industry median Debt-to-Equity is 0.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Suzuken Co and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzuken Co's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzuken Co stock overvalued right now?
Based on GuruFocus' analysis, Suzuken Co (TSE:9987) is currently considered Modestly Undervalued. The stock's GF Value™ is 円5,945.06, compared to a current price of 円5,148.00 — trading 13.4% below its estimated fair value. The current Debt-to-Equity is 0.00. Suzuken Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Suzuken Co (TSE:9987), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzuken Co (TSE:9987) Overvalued in 2026?
Based on GuruFocus' analysis, Suzuken Co stock appears to be undervalued.
The current stock price of 円5,148.00 is trading 13.4% below its estimated GF Value™ of 円5,945.06.
GuruFocus considers Suzuken Co to be Modestly Undervalued.
Key valuation signals for TSE:9987:
Debt-to-Equity: 0.00
GF Value™: 円5,945.06 vs. price of 円5,148.00 (13.4% below fair value)
No single metric tells the full story. See the TSE:9987 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzuken Co Ltd is engaged in the manufacture and sale of pharmaceuticals and medical devices, and in providing insurance, pharmacy, and nursing care services. The company operates through segments, including Pharmaceutical Wholesale business, Healthcare product development business, Specialty Pharmaceuticals Distribution business, Regional medical nursing care support business, and Medical-related Services business. It generates the majority of its revenue from the Pharmaceutical Wholesale Business segment, which sells prescription pharmaceuticals, diagnostic reagents, medical equipment, and medical supplies.
79GF Score
Get the complete analysis for TSE:9987
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9987 has been successfully added to your 
